MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Akero Therapeutics

News headline image
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the Jefferies Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
News headline image
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
From Akero Therapeutics
Via GlobeNewswire
Tickers AKRO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story